Starling Oncology, Inc.

STLN

Exchange: Nasdaq
Industry: Services-Offices & Clinics of Doctors of Medicine
SEC CIK: 0001799191

SEC filings (opens in a new tab)

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.

Other share classesDFPH STLNW

Q3 2022 vs. Q2 2022

How the institutions holding Starling Oncology, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022 All holders in Q2 2022

13F holders of STLN: Q2 2022 compared with Q3 2022
Measure	Q2 2022	Q3 2022	Change
Holders	36	39	+3
Shares	21.9M	23.4M	+1.46M (+6.7%)
Value	$110.9M	$108.4M	−$2.53M (−2.3%)

New holders (5)

Institutions that held Starling Oncology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to STLN in Q3 2022
Institution	Shares	Value	% of portfolio
Zebra Capital Management LLC	27,484	$127.0K	0.48%
Voya Investment Management LLC	13,781	$63.8K	0.00%
Invesco Ltd.	12,642	$58.0K	0.00%
Allspring Global Investments Holdings, LLC	10,919	$50.0K	0.00%
Susquehanna International Group, LLP	10,525	$49.0K	0.00%

Sold out (2)

Institutions that held Starling Oncology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of STLN in Q3 2022
Institution	Shares, Q2 2022	Value, Q2 2022
Millennium Management LLC	121,145	$613.0K
Penserra Capital Management LLC	2,121	$10.0K